GlassScriptPhysician profile
Lizette Day
NPI 1477891166
$4,820.03
in general payments reported to CMS, 2019-2025
33 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $1,131 · 2023: $645 · 2024: $1,040 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,154 · Consulting Fee: $19.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,153.55 |
| Consulting Fee | $19.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $391.96 | 2022-2025 | Ams 700, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $370.00 | 2021-2025 | Saphnelo, Airsupra |
| Abbott Laboratories | $328.82 | 2022-2023 | Freestyle Libre 3, Ensite Precision |
| Abiomed | $286.27 | 2025 | |
| Kyowa Kirin, INC. | $241.10 | 2024-2025 | |
| Lilly USA, LLC | $234.01 | 2024 | Omvoh |
| Acadia Pharmaceuticals INC | $219.61 | 2024-2025 | Daybue |
| Abbvie INC. | $209.96 | 2021-2025 | |
| Si-Bone, INC. | $206.12 | 2021-2022 | |
| Amgen INC. | $173.64 | 2022-2023 | Evenity, Tezspire, Prolia |
| Janssen Pharmaceuticals, INC | $150.52 | 2024 | Spravato |
| Inspire Medical Systems, INC. | $149.92 | 2024 | Inspire |
| Silk Road Medical, INC. | $142.90 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Glaxosmithkline, LLC. | $139.89 | 2021-2023 | Nucala |
| Genentech USA, INC. | $124.99 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $124.99 | 2025 | |
| Axsome Therapeutics, INC. | $124.36 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $122.07 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $114.14 | 2025 | Austedo Xr |
| Amarin Pharma, INC. | $112.65 | 2025 | Vascepa |
| Edwards Lifesciences Corporation | $109.33 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.60 | 2021 | |
| Lucid Diagnostics INC. | $102.14 | 2022 | |
| Stemline Therapeutics INC. | $98.04 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.15 | 2021 | |
| Galderma Laboratories, L.P. | $58.66 | 2024-2025 | |
| Daiichi Sankyo INC. | $46.12 | 2023-2024 | Injectafer |
| Coloplast Corp | $38.55 | 2024 | |
| Janssen Biotech, INC. | $34.89 | 2024 | Stelara |
| Organon LLC | $21.09 | 2025 | Nexplanon |
| Adma Biomanufacturing LLC | $19.12 | 2025 | |
| Tersera Therapeutics LLC | $18.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lizette Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.